TIGIT and neoplasm: 100% the of animals that had originally been cured were able to fully reject the subsequent tumor challenge (Figures 6A, B), highlighting the generation of long-lasting curative antigen-specific CD8+ T cells following anti-TIGIT mAb treatment.